Emerging translational therapies for mesothelioma

Chest. 1999 Dec;116(6 Suppl):455S-460S. doi: 10.1378/chest.116.suppl_3.455s.


Malignant pleural mesothelioma remains a therapeutic and diagnostic problem. Translational mechanisms for treatment of the disease are emerging from newly learned characteristics of the tumor on a molecular, cellular, and extracellular basis. Although slow to reach the clinical arena, these potential strategies do show proof of principle in the in vitro and in vivo settings, and some, including adenoviral molecular chemotherapy, have completed phase I testing. This review describes the rationale and status of these newer treatment ideas.

Publication types

  • Review

MeSH terms

  • Adenoviridae / genetics
  • Adjuvants, Immunologic / therapeutic use
  • Animals
  • Antineoplastic Agents / therapeutic use
  • Autocrine Communication
  • Clinical Trials, Phase I as Topic
  • Gene Targeting
  • Genetic Vectors
  • Humans
  • Mesothelioma / diagnosis
  • Mesothelioma / genetics
  • Mesothelioma / immunology
  • Mesothelioma / pathology
  • Mesothelioma / therapy*
  • Paracrine Communication


  • Adjuvants, Immunologic
  • Antineoplastic Agents